Professor Shao initiated the molecular epidemiological study of HIV in China, and found out the national HIV epidemic strains and their distribution in the population. He led the expert group of the Ministry of Health to play an important technical guiding role in the establishment of a five-level HIV testing laboratory in China, ensuring the standardized and orderly development of AIDS diagnosis in China. He took the lead in calculating the goal of controlling the number of HIV-infected people within10.5 million in 20 10, which became the national planning goal. He suggested that China should not follow the example of the United States in including HIV antigen in blood screening, which saved huge resources for the country. He used the theory of evolution to identify the recent and past AIDS infections and helped the country correctly judge the epidemic situation of AIDS in China. He used smallpox vaccine in China to construct the original AIDS vaccine, and achieved the rare achievement of completely protecting macaques from virus infection in the world, which was reported by science magazine. The vaccine has been approved by the state and is about to start clinical trials. He has published more than 300 papers in domestic and foreign journals, and his research projects have won many national awards and science and technology awards from ministries and commissions.

Shao attaches great importance to uniting domestic teams and participating in international competitions. With the support of the leadership of the Ministry of Health, he organized a team of scientists at home and abroad, obtained the first comprehensive international AIDS research project (CIPRA)150,000 US dollars from NIH, injected more than150,000 US dollars into domestic AIDS research, established an AIDS research platform in line with international standards, and used this as a platform to obtain more than 5 million US dollars for national SARS and avian influenza projects.

The research team led by him has cultivated a new AIDS vaccine with smallpox vaccine in China as the carrier through genetic technology. The first phase of clinical trials ended in 2009 proved the safety of the vaccine. At present, the production of the second phase vaccine has been completed, and it has obtained the technical approval from National Medical Products Administration, and entered the second phase clinical trial. The second phase trial will further verify its immunogenicity, that is, whether it is effective or not. This is the first time in the world that an AIDS vaccine developed with a replicated live virus vector has entered the clinical trial stage. At present, 3 1 person has received the first injection.

According to reports, AIDS vaccines include "live vaccine" and "dead vaccine". Dead vaccines do not reproduce in the human body and decrease with time, while live vaccines divide and reproduce in the human body, which is much more powerful and lasting.

Compared with the two, the dead vaccine is relatively safer, but the cost is high; Live vaccine is not as safe as dead vaccine, but its cost is low. China's research and experiment is a live vaccine: through genetic technology, the HIV fragment is cut off and put on the vaccine carrier for smallpox treatment to cultivate a new vaccine. Compared with the dead vaccine, the "lower cost" of live vaccine is conducive to the promotion and use after success. Recently, China AIDS Vaccine Alliance (CAVI) was formally established at the first China AIDS Vaccine Forum. The alliance is composed of dozens of R&D units engaged in AIDS vaccine research in China, and it is the first AIDS vaccine research organization in China. Shao, one of the founders and chief AIDS expert of China Center for Disease Control and Prevention, told the Science Times reporter at the Asia Regional Consultation on AIDS Vaccine: "The development of AIDS vaccine is an arduous systematic project, which cannot be solved by a single scientific research team in a short time. We must strengthen cooperation if we want to make a difference. CAVI is the best platform for China vaccine research team to unite under the banner of major national science and technology projects, carry out collaborative research and participate in international cooperation. "

Aids vaccine is considered as the best way to prevent AIDS. However, due to various reasons, the research on AIDS vaccine has not been successful for more than 20 years. In 2007, Merck's vaccine, which took 10 years to develop, failed in clinical trials, leading to an unprecedented downturn in global AIDS vaccine research and development.

Fran oise Barr-Sinosi, winner of the 2008 Nobel Prize in Physiology or Medicine and discoverer of HIV, attended the conference and made a speech entitled "25 years of HIV discovery: what have we learned". In an interview with a reporter from Science Times, she pointed out that the research on AIDS vaccine is very difficult. So far, scientists have not obtained a good candidate vaccine, so it is necessary to carry out international cooperation and discover new ideas.

The Asian regional conference was jointly organized by the World Health Organization, UNAIDS, the Global AIDS Vaccine Enterprise Program, the AIDS Research Office of the National Institutes of Health and China CDC. Ceng Yi, an academician of China Academy of Sciences, told the Science Times that there are various AIDS research organizations in developed countries, as well as global organizations. He believes that the establishment of CAVI can not only help UN doctors, but also help to strengthen international exchanges. Our center solemnly declares that the academic paper "2003-201KLOC-0/National Observation Cohort Study on the Prevention of AIDS Transmission between Couples in Single-positive Families in China" published by Professor Shao and other authors in the British medical journal The Lancet does not have any data theft or plagiarism, which meets the relevant requirements for the publication of academic papers.

Hereby declare.

Chinese Center for Disease Control and Prevention

20 13 1 1 5/Solemn Statement Recently, experts from our center published a paper in The Lancet magazine entitled "National Observation Cohort Study on the Prevention of AIDS Transmission between Couples in Single-positive Families in China in 2003 -20 1 1", which met the relevant requirements of the magazine.

Hereby declare. The facts have been clarified and the report is untrue. China CDC Center for AIDS 20 13- 10-30 [reference date: 20 13- 10-30].